logo
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Open Lending

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Open Lending

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Open Lending To Contact Him Directly To Discuss Their Options
If you suffered losses exceeding $75,000 in Open Lending between February 24, 2022 and March 31, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
[You may also click here for additional information]
New York, New York--(Newsfile Corp. - June 27, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Open Lending Corporation ('Open Lending' or the 'Company') (NASDAQ: LPRO) and reminds investors of the June 30, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
[ This image cannot be displayed. Please visit the source: https://images.newsfilecorp.com/files/6455/257018_72dca988343b1bb0_001full.jpg ]
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants: (1) misrepresented the capabilities of the Company's risk-based pricing models; (2) issued materially misleading statements regarding the Company's profit share revenue; (3) failed to disclose the Company's 2021 and 2022 vintage loans had become worth significantly less than their corresponding outstanding loan balances; and (4) misrepresented the underperformance of the Company's 2023 and 2024 vintage loans. As a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
On March 17, 2025, Open Lending announced the postponement of its earnings release and conference call, both originally scheduled for the same day. The company also filed a Form 12b-25, requesting additional time to finalize its financial statements for its annual 10-K report.
On this news, Open Lending's stock price fell $0.40, or 9.3%, to close at $3.91 per share on March 17, 2025, thereby injuring investors.
Subsequently, on March 31, 2025, Open Lending reported a substantial year-over-year increase in its net loss for Q4 2024, largely attributable to the recognition of a valuation allowance on its deferred tax assets, which elevated its income tax expense for the period. Additionally, the company disclosed significant leadership changes.
On this news, Open Lending's stock price fell $1.59, or 57.61%, to close at $1.17 per share on April 1, 2025, thereby injuring investors.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding Open Lending's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
To learn more about the Open Lending Corporation class action, go to www.faruqilaw.com/LPRO or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/257018

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Morning Bid: Wall St flirts with new record
Morning Bid: Wall St flirts with new record

Yahoo

time36 minutes ago

  • Yahoo

Morning Bid: Wall St flirts with new record

By Mike Dolan LONDON (Reuters) - What matters in U.S. and global markets today By Mike Dolan, Editor-At-Large, Finance and Markets The glass appears half full once again. With midyear approaching, the main Wall Street stock indexes are back within a hair's breadth of new records, helped along by a weakening dollar, the prospect of lower borrowing rates, increasing trade optimism and a renewed focus on the artificial intelligence theme. Throw in some positive tax and regulatory twists, and now we're likely to see new highs for the S&P 500 and Nasdaq later today. It's Friday, so today I'll provide a quick overview of what's happening in global markets and then offer you some weekend reading suggestions away from the headlines. Today's Market Minute * The United States has reached an agreement with China on how to expedite rare earth shipments to the U.S., a White House official said on Thursday, amid efforts to end a trade war between the world's biggest economies. * European Union leaders discussed new proposals from the United States on a trade deal at a summit in Brussels on Thursday, with Commission President Ursula von der Leyen not ruling out tariff talks could fail and saying "all options remain on the table". * Iran would respond to any future U.S. attack by striking American military bases in the Middle East, Supreme Leader Ayatollah Ali Khamenei said on Thursday, in his first televised remarks since a ceasefire was reached between Iran and Israel. * U.S. Treasury Secretary Scott Bessent on Thursday asked Republicans in Congress to remove a "retaliatory tax" proposal that targets foreign investors from their sweeping budget legislation, as lawmakers struggled to find a path forward on the bill. * What will be the biggest pain trades in the second half of 2025? ROI columnist Jamie McGeever discusses the most vulnerable positions. Wall St flirts with new record While still underperforming the MSCI's all-country index for the year so far, and lagging euro zone stocks by some 20% in dollar terms in 2025, the S&P500 has all but completed a remarkable 20% round trip from the peak of February to the troughs of April and back. The VIX 'fear index' ebbed to its lowest in four months, while gold prices slipped to their lowest in almost a month. With more than 40% of S&P500 revenues coming from overseas, the dollar's slide to 3-year lows this week spotlights a 10%-plus currency tailwind in 2025. The greenback remained near the year's lows on Friday. And even though President Donald Trump's harrying of Federal Reserve Chair Jerome Powell unnerves many about the long-term inflation impact of threatening Fed independence, it has stepped up bets about a resumption of interest rate cuts - and most clearly after Powell's term ends next year. While markets awaited the latest U.S. May inflation update later on Friday - with oil prices brushing off the latest Middle East conflict to resume a near 20% year-on-year drop - two and 10-year Treasury yields fell to their lowest since early May on Thursday. The bond market has been soothed in part by this week's Fed proposal on overhauling how much capital large global banks must hold against relatively low-risk assets, part of a bid to boost banks' participation in Treasury markets. But markets got a further lift overnight from signs of some movement on bilateral trade negotiations ahead of July 9's expiry of the 90-day pause on Trump's sweeping tariff hikes. The White House said the United States reached an agreement with China on how to expedite rare earth shipments to the U.S. European Union leaders discussed new proposals from the United States on a trade deal at a summit in Brussels late on Thursday, with Commission President Ursula von der Leyen saying "all options remain on the table". German Chancellor Friedrich Merz urged the EU to do a "quick and simple" trade deal rather than a "slow and complicated" one, even as French President Emmanuel Macron struck a cautious note. And while the U.S. fiscal bill is still struggling through the Senate, there was an important development on tax provisions that may ease foreign investor concerns. Treasury Secretary Scott Bessent asked Republicans in Congress to remove a "retaliatory tax" proposal - the controversial Section 899 that targets foreign investors with higher tax in retaliation for any overseas disputes. Justifying the removal, Bessent said that under a G7 agreement, a 15% global corporate minimum tax will not apply to U.S. companies under "Pillar 2" of the Organization for Economic Cooperation and Development tax deal. The latest economic numbers, meantime, were a mixed bag but show few signs of a sharp downturn yet. Durable goods orders boomed in May well above forecasts, while the labor market remained resilient with a drop in weekly jobless claims. May trade data, on the other hand, showed a sharp drop in exports. As the second-quarter earnings season comes into view next month, the longer-term AI investment theme was given a fresh spur from an above-forecast revenue readout from Micron Technology - even though its stock ended lower on Thursday. AI darling Nvidia hit a new record high, however, up more than 80% from the lows of April. In other corporate news, Nike's shares jumped 10% overnight as its first-quarter revenue outlook exceeded market expectations. Elsewhere, stocks in Europe were sharply higher on Friday - chiming with Wall Street. They have been boosted by the defense spending push at this week's NATO summit and as details of Germany's big fiscal stimulus unfolded. German lawmakers on Thursday passed a multi-billion-euro package of fiscal relief measures to support companies and boost investment, involving corporate tax breaks amounting to almost 46 billion euros ($54 billion) from this year through to 2029. Despite the positive noises on a U.S. trade deal, Chinese stocks bucked the global trend and were in the red on Friday. China's industrial profits swung back into sharp decline, falling 9.1% in May from a year earlier, as factory activity slowed in the face of broader economic stress. There was better news in Japan as core consumer inflation in Tokyo slowed sharply in June. Tech stocks led the Nikkei up more than 1%. Weekend reads: * TARIFF DAMAGE: Even though President Donald Trump appears to have retreated from his more extreme trade tariff plans due to market, industry and political pushback, trade barriers will damage the economy over the next decade. So claims a Peterson Institute paper by Warwick McKibbin, Marcus Noland and Geoffrey Shuetrim, who estimate the impact under five different scenarios - which get worse the bigger the retaliation overseas and the higher the country risk premium demanded by global investors. "Contrary to Trump's promises to revive U.S. industry, America's manufacturing and agriculture sectors see disproportionate losses in production and employment due to his tariffs." * OPAQUE DEBT: Global sovereign debt vulnerability is rising and 54% of low-income countries are already in or at high risk of debt distress, with many spending more on debt repayments than on education, healthcare and infrastructure combined. With frequent global shocks adding to the risk, the World Bank's Axel van Trotsenburg argues on Project Syndicate that debt obligations are now more complex, with a wider range of creditors and some borrowing occurring behind closed doors and outside the scrutiny of oversight mechanisms. "Without urgent action to improve transparency, unsustainable debt-service burdens in the developing world will become common." * UKRAINE VS RUSSIA IN AFRICA: On Africa's dry western tip, Mauritania has become an unlikely staging post for Ukraine's increasingly global struggle with its adversary Russia. Reuters' Jessica Donati and Olena Harmash detail Kyiv's Africa Strategy in seeking allies with aide and embassies - countering Russia's much more entrenched presence in the continent. * SIU SIMPLE: With much attention on the European Union's ability to attract or unlock much-needed investment capital, accelerating its capital markets integration - or Savings and Investments Union - is seen as critical. Nicholas Veron at Bruegel proposes catalyzing this by hardening a central supervisory system to replace the current complex hybrid of a central agency - the European Securities and Markets Authority - alongside national supervisory bodies. "The way to reform it is by pooling all capital market supervisory authority into a transformed multicentric ESMA that would operate mostly through its own offices in EU countries, ensuring supervisory consistency and no preferential treatment for any single financial centre." * WEGOVY TEEN IMPACT: A fast-growing cohort of American teens who have chosen to take Novo Nordisk's weight-loss drug Wegovy, placing them at the forefront of a monumental shift in the treatment of childhood obesity. A Reuters special report by Chad Terhune and Robin Respaut found children who had taken Wegovy or a similar weight-loss drug, to speak with them about their experiences. The reporters spent more than a year closely following four teens and their families to examine in detail the impact of treatment. Chart of the day: U.S. stock markets have completed a remarkable 20% round trip since February to stand back at the brink of new records - with the S&P500 up more than 10% on this time last year. Today's events to watch * U.S. May personal consumption expenditures inflation gauge (0830EDT) University of Michigan's final June consumer survey (10:00 AM EDT) * New York Federal Reserve President John Williams and Cleveland Fed President Beth Hammack speak Opinions expressed are those of the author. They do not reflect the views of Reuters News, which, under the Trust Principles, is committed to integrity, independence, and freedom from bias. (By Mike Dolan; Editing by Anna Szymanski) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

B. Riley Financial announces $117.8M sale of GlassRatner to TorQuest Partners
B. Riley Financial announces $117.8M sale of GlassRatner to TorQuest Partners

Yahoo

time40 minutes ago

  • Yahoo

B. Riley Financial announces $117.8M sale of GlassRatner to TorQuest Partners

B. Riley Financial (RILY) announced it has sold its advisory services business, GlassRatner Advisory & Capital Group and B. Riley Farber Advisory, to funds managed by TorQuest Partners for $117.8M. BRF expects to record a gain on the sale of GlassRatner, which it acquired in August 2018, of approximately $66M. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on RILY: Disclaimer & DisclosureReport an Issue Largest borrow rate increases among liquid names B Riley Financial Receives Nasdaq Compliance Extension B. Riley Financial granted extension from Nasdaq regarding listing rules B Riley Financial Faces Nasdaq Delinquency Notification B. Riley Financial receives expected delinquency notification from Nasdaq

Mystery $33 Billion Medicine Fortune Collapses in Days
Mystery $33 Billion Medicine Fortune Collapses in Days

Yahoo

time2 hours ago

  • Yahoo

Mystery $33 Billion Medicine Fortune Collapses in Days

(Bloomberg) -- When Yat-Gai Au was worth $33 billion on paper, he wasn't in his Hong Kong office. Philadelphia Transit System Votes to Cut Service by 45%, Hike Fares US Renters Face Storm of Rising Costs Squeezed by Crowds, the Roads of Central Park Are Being Reimagined Mapping the Architectural History of New York's Chinatown US State Budget Wounds Intensify From Trump, DOGE Policy Shifts One week later, when his net worth plunged to $10.1 billion, he wasn't around either. Officers at the headquarters of Regencell Bioscience Holdings Ltd said both times that Au only takes short visits there, before turning away reporters. The firm, a Nasdaq-listed, Cayman Islands-incorporated traditional Chinese medicine company, occupies the whole 9th floor of a tower in Hong Kong's bustling Causeway Bay, including a reception area with a large table-tennis table. Little is still known about the tiny, money-losing company whose shares exploded 82,000% higher and suddenly made Au, its chief executive officer with an 86% stake, richer on paper than some of the city's tycoons like Li Ka-shing. The fleeting nature of its rip-roaring rally has captivated and mystified observers from the US to Hong Hong. Morning Brew, a popular business account on X, flagged its stock move and wondered: 'Is there something I'm missing?' Regulators in the US, which closely monitor wild swings in stock prices, might soon be asking the same question, according to experts. The Financial Industry Regulatory Authority, the watchdog for broker-dealers, has repeatedly warned that small, cheap stocks are more susceptible to fraud. These companies can be targets for pump-and-dump schemes in which fraudsters inflate the stock price and quickly sell their shares. The US Securities and Exchange Commission, meanwhile, has been increasingly wary about companies listed on US exchanges that are based overseas — and Regencell checks both boxes. The regulator on June 4 called on the public to weigh in on whether the agency needed to amend the definition of what's called a foreign private issuer, potentially limiting the number of companies that qualify for special status that lets them avoid filing quarterly financial reports or disclosing when executives buy or sell company shares. 'This is an example of very unusual movements in share prices,' said Richard Harris, founder and chief executive of Port Shelter Investment Management in Hong Kong. 'These movements could certainly trigger interest by investigators.' The SEC and Finra declined to comment on whether they were monitoring Regencell's moves. Finra's mission is to protect investors and safeguard market integrity, spokesperson Rita De Ramos said. 'In line with that mission, Finra continues to monitor the market for unusual trading activity, as part of our normal course of action.' Regencell didn't respond to emails and phone calls for comment on its stock performance and its founder's fortune. The company's shares have retreated 74% from their peak, shrinking Au's stake to about $8.6 billion as of June 26. Founded in 2014, Regencell's main line of business is marketing and licensing traditional treatments for ADHD and autism spectrum disorder developed by the founder's father, Sik-Kee Au. It has exclusive rights over his traditional medicinal formulas, trademarked under the name Brain Theory. The firm posted net losses of $4.4 million and $6.1 million, respectively, for the fiscal years ended June 2024 and 2023, according to filings. Its chief medical officer position has been vacant since the last doctor to hold the job resigned in 2022. The younger Au attended the Haas School of Business at the University of California, Berkeley and worked at Deutsche Bank AG in the late 1990s. He suffered from learning disorders and speech problems, had poor grades and an uncontrollable temper, according to a video post on the company's Instagram account. Regencell's mission is to 'improve and save lives using a natural and holistic TCM formula to treat ADHD and ASD,' according to the same video. The company's official Instagram account has more than half a million followers. BeOne Medicines Ltd., the largest healthcare firm listed in Hong Kong, has just over 2,500. Regencell built out a following with the help of social-media campaigns on the platform that offered free tickets for Taylor Swift concerts in the US and Asia. The company's second-largest shareholder is Digital Mobile Venture Ltd., a firm ultimately owned by Taiwan's Samuel Chen and his wife Fiona Chang. Chen was an investor whose early investments in Zoom Video Communications Inc. made him a fortune when the company's stock soared almost 1,500% during the pandemic. Chen, Chang and their children own a 55% stake in Taipei-based Polaris Group, a biotechnology company developing anti-cancer drugs. He's also the biggest shareholder of Sonix Technology Co., a provider of integrated circuits listed in Taipei. Bloomberg News received no reply to emails sent to Polaris and Sonix seeking comments from Chen. While monitoring for wild price swings used to be done manually, the SEC and Finra now have programs to automatically detect market anomalies, according to Erik Gordon, professor at the University of Michigan's Ross School of Business. They can also compel companies to share if they know why their stock price soared or crashed or whether insiders cashed in at the peak. The absence of profits or revenues at Regencell isn't an automatic red flag; plenty of early-stage pharmaceutical companies have similar finances, he said. On June 18, two men and a woman arrived at Regencell's Hong Kong office seeking information about treatment for ADHD and dementia. They said they read about the stock's surge before arriving. The visitors were also turned away. An employee said its staff were not doctors, and directed them to the company's website. 'Early stage pharma companies can jump from a dollar to four dollars in 90 seconds if there's some news about one of their drugs under development doing well in a clinical trial,' Gordon said. In this case, 'what's interesting is there's no news.' --With assistance from Dylan Sloan. (Adds stock decline since peak and Yat-Gai Au's stake in 11th paragraph.) America's Top Consumer-Sentiment Economist Is Worried How to Steal a House Inside Gap's Last-Ditch, Tariff-Addled Turnaround Push Apple Test-Drives Big-Screen Movie Strategy With F1 Luxury Counterfeiters Keep Outsmarting the Makers of $10,000 Handbags ©2025 Bloomberg L.P. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store